Languages
  • English
  • Español
  • français
  • русский
  • العربية
  • info@iozk.de
    • Deutsch Deutsch Deutsch de
    • English English Englisch en
    • Español Español Spanisch es
    • Русский Русский Russisch ru
    IOZK
    • Startseite
    • Das IOZK
      • Philosophie
      • Team
      • Behandlungszentrum
      • Laboratorien
      • Karriere
      • Anreise und Übernachtung
      • Patientenbroschüre
    • Die IOZK Immuntherapie
      • IOZK-Immuntherapie
      • IO-VAC Impfstoff
      • Behandlungsablauf
      • IOZK Immuntherapie nach Krebsarten
      • Therapiekosten
      • FAQ
    • Fachwissen
      • IOZK Publikationen
      • Int. Publikationen
      • Wissenswertes
    • Aktuelles
    • Kontakt
    • Suche
    • Menü

    Stefaan Van Gool MD. PhD.

    Medizinischer Leiter der Translationalen Onkologie am IOZK

    Tumorimmunologe mit Schwerpunkt Hirntumore

    Stefaan Van Gool MD. PhD., ist Facharzt für pädiatrische Hämato-Onkologie mit dem Schwerpunkt Hirntumore. Von 2001 bis 2004 war er Leitender klinischer Prüfarzt am Förderfonds für wissenschaftliche Forschung Flandern. Zwischen 2006 und 2016 hatte er eine Ordentliche Professur an der medizinischen Fakultät der Katholischen Universität Leuven inne. Dort leitete er von 2012 bis 2015 das Labor für Pädiatrische Immunologie. Er ist Autor von annähernd 200 wissenschaftlichen Artikeln in internationalen Journalen.

    In Anerkennung seiner wissenschaftlichen Leistungen erhielt er eine Vielzahl von Ehrungen:

    1995 Schweisguth Preis der International Society of Paediatric Oncology
    1996 Nycomed Preis der International Society of Paediatric Oncology
    1998 Preis der Rik en Nel Wouters-Stiftung für Krebsforschung (mit Ludwig Van den Hove)
    Von 2005 bis 2009 war er der Koordinator der europäischen Expertengruppe für High Grade Glioma
    Seit 2008 ist er Mitglied des Obersten Gesundheitsgerichtshofs in Belgien
    Von 2014 bis 2017 fungierte er als Ko-Vorsitzender der Arbeitsgruppe Hirntumore der European Society for Paediatric Oncology.

    Am IOZK steht er dem Ärzteteam vor und ist verantwortlich für die Planung und Durchführung der IOZK-Immuntherapie. In der Arzneimittelherstellung fungiert er als Sachkundige Person (GMP) und verantwortliche ärztliche Person.

    „Da jeder Tumor anders ist, erzielt man die besten Ergebnisse, wenn man mit patienteneigenen dendritischen Zellen gegen den einzigartigen Satz von Tumorzellen vorgeht“

    Stefaan Van Gool MD. PhD.

    Sammlung: Wissenschaftliche Beiträge und internationale Publikationen von Stefaan Van Gool MD. PhD

    Stefaan van Gool ist Herausgeber einer Sonderausgabe im Journal of Molecular Sciences

    2023-01-23/in Brain Tumors in Children, IOZK Aktuelles, IOZK Veröffentlichungen /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2020/11/IOZK_team_van-gool_175828-ret.jpg 518 690 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2023-01-23 16:08:352023-01-25 16:42:45Stefaan van Gool ist Herausgeber einer Sonderausgabe im Journal of Molecular Sciences

    Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy

    2022-10-27/in International Publications, IOZK Veröffentlichungen /von 2022-10-27 / Int J Mol Sci 2022 Oct;23(21)
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2022-10-27 / Int J Mol Sci 2022 Oct;23(21) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2022-10-27 / Int J Mol Sci 2022 Oct;23(21)2022-10-27 00:00:002023-01-31 13:01:45Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy

    Poster presentation at the annual meeting of the Association for Cancer Immunotherapy

    2022-06-02/in Glioblastoma, International Publications, IOZK bei Fachtagungen, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2022-02-28 / Biomedicines 2022 Feb;10(3) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2022-02-28 / Biomedicines 2022 Feb;10(3)2022-06-02 00:00:002022-06-27 12:26:23Poster presentation at the annual meeting of the Association for Cancer Immunotherapy

    Poster presentation at the International Symposium on Pediatric Neuro-Oncology

    2022-06-02/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2022-02-28 / Biomedicines 2022 Feb;10(3) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2022-02-28 / Biomedicines 2022 Feb;10(3)2022-06-02 00:00:002022-06-27 12:27:29Poster presentation at the International Symposium on Pediatric Neuro-Oncology

    Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

    2022-02-16/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2022-02-16 / Genes Immun 2022 Feb; https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2022-02-16 / Genes Immun 2022 Feb;2022-02-16 00:00:002022-02-21 07:49:56Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

    Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

    2021-07-04/in International Publications, IOZK Veröffentlichungen /von 2021-07-04 / Cancer Immunol Immunother 2021 Jul;
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2021-07-04 / Cancer Immunol Immunother 2021 Jul; https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2021-07-04 / Cancer Immunol Immunother 2021 Jul;2021-07-04 00:00:002021-11-15 12:29:15Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

    DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival

    2021-02-25/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2021-02-25 / Neuro Oncol 2021 02;23(2):240-250
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2021-02-25 / Neuro Oncol 2021 02;23(2):240-250 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2021-02-25 / Neuro Oncol 2021 02;23(2):240-2502021-02-25 00:00:002021-11-15 19:08:36DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival

    Impaired DNA repair in mouse monocytes compared to macrophages and precursors

    2020-12-30/in International Publications, IOZK Veröffentlichungen /von 2020-12-30 / DNA Repair (Amst) 2020 Dec;98:103037
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-12-30 / DNA Repair (Amst) 2020 Dec;98:103037 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-12-30 / DNA Repair (Amst) 2020 Dec;98:1030372020-12-30 00:00:002021-11-15 13:16:40Impaired DNA repair in mouse monocytes compared to macrophages and precursors

    Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

    2020-12-24/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-12-24 / Cancers (Basel) 2020 Dec;13(1) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)2020-12-24 00:00:002021-11-15 13:17:14Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

    Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit

    2020-07-23/in International Publications, IOZK Veröffentlichungen /von 2020-07-23 / Biomedicines 2020 Jul;8(8)
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-07-23 / Biomedicines 2020 Jul;8(8) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-07-23 / Biomedicines 2020 Jul;8(8)2020-07-23 00:00:002021-11-15 19:51:32Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit

    Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies

    2020-06-30/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-6462020-06-30 00:00:002021-11-15 13:19:48Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies

    IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)

    2020-06-02/in IOZK Veröffentlichungen /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2020-06-02 12:45:162020-06-02 13:07:50IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)

    Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience

    2020-05-19/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-05-19 / Medicines (Basel) 2020 May;7(5)
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2020-05-19 / Medicines (Basel) 2020 May;7(5) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2020-05-19 / Medicines (Basel) 2020 May;7(5)2020-05-19 00:00:002021-11-15 20:10:42Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience

    Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

    2019-08-30/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2019-08-30 / Biomedicines 2019 Aug;7(3) https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2019-08-30 / Biomedicines 2019 Aug;7(3)2019-08-30 00:00:002021-11-15 13:22:59Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

    Symposium & Fortbildung am IOZK: Immuntherapie in der Neuroonkologie, Fr. 06.09.2019

    2019-06-12/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Einladung-Symposium.jpg 999 2000 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2019-06-12 19:14:282019-07-18 09:34:50Symposium & Fortbildung am IOZK: Immuntherapie in der Neuroonkologie, Fr. 06.09.2019

    Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy

    2019-04-01/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-2051
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-2051 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2019-04-01 / Anticancer Res 2019 Apr;39(4):2043-20512019-04-01 00:00:002021-11-15 20:00:34Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy

    Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group

    2018-08-01/in Brain Tumors in Children, International Publications, IOZK Veröffentlichungen /von 2018-08-01 / Lancet Oncol 2018 08;19(8):e419-e428
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2018-08-01 / Lancet Oncol 2018 08;19(8):e419-e428 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2018-08-01 / Lancet Oncol 2018 08;19(8):e419-e4282018-08-01 00:00:002021-11-15 19:56:02Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group

    IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“

    2018-07-24/in IOZK Veröffentlichungen /von root
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 root https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg root2018-07-24 18:56:262020-05-27 11:18:50IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: "Austin Oncology Case Report"

    IOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charité Berlin

    2018-05-01/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2018-05-01 11:21:402019-09-09 11:30:03IOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charité Berlin

    IOZK Vortrag über die Effekte der multimodalen Immuntherapie bei einem Ponsgliom mit Hilfe der Analysemethode Flüssigbiopsie.

    2018-04-11/in Externe Meldungen, IOZK bei Fachtagungen /von root
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 root https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg root2018-04-11 18:59:532020-05-27 11:21:16IOZK Vortrag über die Effekte der multimodalen Immuntherapie bei einem Ponsgliom mit Hilfe der Analysemethode Flüssigbiopsie.

    IOZK Vortrag von Stefaan Van Gool: IOZK Immuntherapie bei DIPG Ponsgliom, Konferenz der Society for Neuro-Oncology, San Francisco

    2017-11-16/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2017-11-16 16:30:162019-02-10 11:36:36IOZK Vortrag von Stefaan Van Gool: IOZK Immuntherapie bei DIPG Ponsgliom, Konferenz der Society for Neuro-Oncology, San Francisco

    Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival

    2017-10-24/in International Publications, IOZK Veröffentlichungen /von 2017-10-24 / Sci Rep 2017 10;7(1):13902
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2017-10-24 / Sci Rep 2017 10;7(1):13902 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2017-10-24 / Sci Rep 2017 10;7(1):139022017-10-24 00:00:002021-11-15 20:01:44Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival

    Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade

    2017-07-19/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2017-07-19 / Int J Cancer 2017 11;141(9):1891-1900
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2017-07-19 / Int J Cancer 2017 11;141(9):1891-1900 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2017-07-19 / Int J Cancer 2017 11;141(9):1891-19002017-07-19 00:00:002021-11-15 20:03:02Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade

    Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy

    2017-04-27/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2017-04-27 / Sci Rep 2017 04;7(1):1217
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2017-04-27 / Sci Rep 2017 04;7(1):1217 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2017-04-27 / Sci Rep 2017 04;7(1):12172017-04-27 00:00:002021-11-15 20:07:45Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy

    IOZK Artikel im Austin Oncology Case Reports über Krebsimpfstoffe

    2017-03-01/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2017-03-01 12:12:242020-05-27 11:24:21IOZK Artikel im Austin Oncology Case Reports über Krebsimpfstoffe

    Artikel über Stefaan Van Gool als Kinderneuroonkologe in der Washington Post

    2017-02-01/in IOZK In der Presse /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2017-02-01 12:17:052019-07-15 15:44:45Artikel über Stefaan Van Gool als Kinderneuroonkologe in der Washington Post

    Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease

    2017-01-21/in Brain Tumors in Children, International Publications, IOZK Veröffentlichungen /von 2017-01-21 / J Neurooncol 2017 04;132(2):255-266
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2017-01-21 / J Neurooncol 2017 04;132(2):255-266 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2017-01-21 / J Neurooncol 2017 04;132(2):255-2662017-01-21 00:00:002021-11-15 20:06:08Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease

    Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group

    2016-07-12/in Brain Tumors in Children, Dendritic Cells, International Publications /von 2016-07-12 / Cytotherapy 2016 09;18(9):1178-86
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2016-07-12 / Cytotherapy 2016 09;18(9):1178-86 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2016-07-12 / Cytotherapy 2016 09;18(9):1178-862016-07-12 00:00:002020-06-23 10:01:20Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group

    Veröffentlichung von Stefaan Van Gool MD. PhD.: Electroporation of Dendritic Cells with WT1, Survivin, and TriMix​

    2016-05-01/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2016-05-01 13:48:072019-02-12 13:48:48Veröffentlichung von Stefaan Van Gool MD. PhD.: Electroporation of Dendritic Cells with WT1, Survivin, and TriMix​

    IOZK Beitrag in der Fachzeitschrift für Orthomolekulare Medizin, Sonderheft: Onkologie

    2016-02-01/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2016-02-01 13:56:132020-05-27 11:44:02IOZK Beitrag in der Fachzeitschrift für Orthomolekulare Medizin, Sonderheft: Onkologie

    Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines

    2016-01-14/in Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen /von 2016-01-14 / Front Immunol 2015;6:663
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2016-01-14 / Front Immunol 2015;6:663 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2016-01-14 / Front Immunol 2015;6:6632016-01-14 00:00:002021-11-15 13:26:00Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines

    Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma

    2015-09-11/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-09-11 / Oncoimmunology 2016 Feb;5(2):e1083669
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2015-09-11 / Oncoimmunology 2016 Feb;5(2):e1083669 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2015-09-11 / Oncoimmunology 2016 Feb;5(2):e10836692015-09-11 00:00:002021-11-15 13:26:23Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma

    Stefaan Van Gool wechselt von der Universität Leuven zum IOZK

    2015-09-01/in IOZK Meldungen /von IOZK
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 IOZK https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg IOZK2015-09-01 16:53:062019-02-12 16:53:40Stefaan Van Gool wechselt von der Universität Leuven zum IOZK

    Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients

    2015-08-27/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-08-27 / Biomed Res Int 2015;2015:842923
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2015-08-27 / Biomed Res Int 2015;2015:842923 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2015-08-27 / Biomed Res Int 2015;2015:8429232015-08-27 00:00:002021-11-15 13:26:51Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients

    Brain Tumor Immunotherapy: What have We Learned so Far?

    2015-06-17/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-17 / Front Oncol 2015;5:98
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2015-06-17 / Front Oncol 2015;5:98 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2015-06-17 / Front Oncol 2015;5:982015-06-17 00:00:002021-11-15 13:27:21Brain Tumor Immunotherapy: What have We Learned so Far?

    Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model

    2015-06-13/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-322015-06-13 00:00:002021-11-15 13:28:49Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model

    Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?

    2015-01-15/in Glioblastoma, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2015-01-15 / J Cancer 2015;6(3):203-17
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2015-01-15 / J Cancer 2015;6(3):203-17 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2015-01-15 / J Cancer 2015;6(3):203-172015-01-15 00:00:002021-11-15 13:29:28Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?

    Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells

    2014-05-13/in Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2014-05-13 / Cytotherapy 2014 Jul;16(7):946-64
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2014-05-13 / Cytotherapy 2014 Jul;16(7):946-64 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2014-05-13 / Cytotherapy 2014 Jul;16(7):946-642014-05-13 00:00:002021-11-15 13:30:25Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells

    Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies

    2014-05-02/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer, Uterine Cancer /von 2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-11
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-11 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-112014-05-02 00:00:002021-11-15 13:30:54Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies

    Dendritic cell immunotherapy in uterine cancer

    2014-01-01/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Uterine Cancer /von 2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-7
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-7 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-72014-01-01 00:00:002021-11-15 13:31:55Dendritic cell immunotherapy in uterine cancer

    Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial

    2013-12-01/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Uterine Cancer /von 2013-12-01 / Anticancer Res. 2013 Dec;33(12):5495-500
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2013-12-01 / Anticancer Res. 2013 Dec;33(12):5495-500 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2013-12-01 / Anticancer Res. 2013 Dec;33(12):5495-5002013-12-01 00:00:002021-11-15 13:32:21Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial

    Myeloid-derived suppressor cells in glioma

    2013-11-12/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-4062013-11-12 00:00:002021-11-15 13:32:44Myeloid-derived suppressor cells in glioma

    Dendritic cell-based immunotherapy in ovarian cancer

    2013-11-06/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer /von 2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2013-11-06 / Oncoimmunology 2013 Dec;2(12):e270592013-11-06 00:00:002021-11-15 13:33:23Dendritic cell-based immunotherapy in ovarian cancer

    Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials

    2013-10-01/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-6
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-6 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-62013-10-01 00:00:002021-11-15 14:42:34Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials

    Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma

    2013-09-01/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer /von 2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-92013-09-01 00:00:002021-11-15 14:43:00Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma

    Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

    2013-08-14/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-48
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-48 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-482013-08-14 00:00:002021-11-15 14:43:30Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

    Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

    2012-04-22/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-442012-04-22 00:00:002021-11-15 14:43:58Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

    Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma

    2010-09-01/in Dendritic Cells, Endometrial Cancer, International Publications, IOZK Veröffentlichungen /von 2010-09-01 / Anticancer Res. 2010 Sep;30(9):3709-14
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2010-09-01 / Anticancer Res. 2010 Sep;30(9):3709-14 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2010-09-01 / Anticancer Res. 2010 Sep;30(9):3709-142010-09-01 00:00:002021-11-15 14:44:41Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma

    Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours

    2010-04-01/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-25
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-25 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-252010-04-01 00:00:002021-11-15 14:45:11Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours

    Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination

    2009-10-27/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-73
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-73 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-732009-10-27 00:00:002021-11-15 14:45:35Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination

    Dendritic cell therapy of high-grade gliomas

    2009-10-01/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-712
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-712 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2009-10-01 / Brain Pathol. 2009 Oct;19(4):694-7122009-10-01 00:00:002021-11-15 14:46:05Dendritic cell therapy of high-grade gliomas

    Vaccine therapy in patients with renal cell carcinoma

    2009-01-30/in Hypernephroma, International Publications, IOZK Veröffentlichungen /von 2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-422009-01-30 00:00:002021-11-15 14:46:31Vaccine therapy in patients with renal cell carcinoma

    Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

    2008-05-15/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-104
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-104 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-1042008-05-15 00:00:002021-11-15 14:47:03Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

    Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells

    2007-03-15/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-40
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-40 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-402007-03-15 00:00:002021-11-15 15:39:28Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells

    Dendritic cell vaccination in patients with malignant gliomas: current status and future directions

    2006-11-01/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2006-11-01 / Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-1000
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2006-11-01 / Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-1000 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2006-11-01 / Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-10002006-11-01 00:00:002021-11-15 15:39:05Dendritic cell vaccination in patients with malignant gliomas: current status and future directions

    Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

    2004-11-01/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-622004-11-01 00:00:002021-11-15 15:38:39Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

    Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report

    2004-05-01/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7
    Weiterlesen
    https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 0 0 2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7 https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg 2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-72004-05-01 00:00:002021-11-15 15:38:16Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report

    Weitere Informationen zu diesem Thema:

    • Team
    • IOZK Immuntherapie
    • Viren gegen Krebs
    • Bedeutung von dendritischen Zellen

    This post is also available in: Englisch Spanisch Russisch

    Das IOZK

    • Philosophie
    • Team
    • Behandlungszentrum
    • Laboratorien
    • Karriere
    • Anreise und Übernachtung
    • IOZK Patientenbroschüre

    SPECIALISTS IN IMMUNO-ONCOLOGY

    NEUESTE BEITRÄGE

    • Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022
    • Stefaan van Gool ist Herausgeber einer Sonderausgabe im Journal of Molecular Sciences
    • Hyperthermie die vierte Säule in der Onkologie – Trailer zum Film
    • Modulated electrohyperthermia in locally advanced cervical cancer: Results of an observational study of 95 patients
    • [Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma]

    ERKLÄRFILME & PATIENTENBERICHTE

    Die IOZK Patientenbroschüre

    Schlagwörter

    Brustkrebs Case Report Check-Point-Inibitoren Chemotherapie Curamun Curcumin Dendritische Zellen Dr. Dirk Lorenzen Dr. Wilfried Stücker Evidenzbasierte Medizin Flüssigbiopsie German Medical Award Glioblastom Hirntumor Hyperthermie Immuntherapie IO-Vac IOZK-Symposium IOZK Arbeitsgruppe IOZK Immuntherapie IOZK Patientenbroschüre IOZK Stiftung Newcastle Disease Virus Nobelpreis für Medizin Onkologie Onkolytische Viren Paul Ehrlich-Preis Personalisierte Medizin Ponsgliom Prof. Dr. rer. nat. Volker Schirrmacher Prostatakrebs Publikationen: Dr. Wilfried Stücker Publikationen: Prof. Dr. rer. nat. Volker Schirrmacher Publikationen: Stefaan Van Gool MD. PhD. Stefaan Van Gool MD. PhD. Target Therapie Virotherapie
    IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
    Hohenstaufenring 30–32
    50674 Köln | Deutschland

    T: +49 (0)221 – 420 399 25
    E-Mail: info@iozk.de

    Das IOZK

    • Philosophie
    • Team
    • Behandlungszentrum
    • Laboratorien
    • Karriere
    • Anreise und Übernachtung
    • IOZK Patientenbroschüre

    Die IOZK Immuntherapie

    • IOZK-Immuntherapie
    • Der IO-VAC® Impfstoff
    • Behandlungsablauf
    • IOZK Immuntherapie nach Krebsarten
    • Therapiekosten
    • FAQ

    Aktuelles und Int. Publikationen

    • Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022
    • Stefaan van Gool ist Herausgeber einer Sonderausgabe im Journal of Molecular Sciences
    • Hyperthermie die vierte Säule in der Onkologie – Trailer zum Film
    © 2019 IOZK Immun-Onkologisches Zentrum Köln
    • Impressum
    • Datenschutzerklärung
    • Cookie-Einstellungen
    • Presse
    Nach oben scrollen